Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort
Journal of Korean Medical Science · 2026 · 41 (42)
DOI: 10.3346/jkms.2026.41.e258 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Korean Medical Science, 2026. Verfasst von Hyo Jung Cho und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea. Hauptthemen laut MEDLINE: Estradiol, Liver Cirrhosis, Fatty Liver. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea, Ajou University Medical Center.
Abstract (Originalsprache)
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) shows marked sexual dimorphism, with estrogen believed to be liver-protective. This study investigated the independent association between circulating estradiol levels, MASLD, and advanced fibrosis (defined by fibrosis index-4 [FIB-4] ≥ 1.3) in Korean women, utilizing stratified analyses by age and body mass index (BMI) to identify context-dependent effects. METHODS: We analyzed cross-sectional data from the Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry, including 995 women (352 with MASLD). Multivariable logistic regression was used to evaluate the association of log2-transformed estradiol with MASLD and high-risk fibrosis, stratified by age (proxy for menopausal status, ≥ 50 vs. < 50 years) and BMI (≥ 25 vs. < 25 kg/m²). RESULTS: In multivariable analysis of the entire cohort, lower estradiol levels were independently associated with MASLD (adjusted odds ratio [aOR], 0.88; 95% confidence interval [CI], 0.79-0.98; P = 0.025). This association was particularly evident in women with lower BMI (aOR, 0.84; 95% CI, 0.71-0.98), but not in high BMI women, suggesting attenuation of estrogen's metabolic protection in the presence of obesity. Estradiol demonstrated a strong and consistent inverse association with FIB-4 ≥ 1.3 (aOR, 0.65; 95% CI, 0.56-0.75; P < 0.001). This protective antifibrotic effect remained robust across BMI strata and was also significant in women aged ≥ 50 years (aOR, 0.70; 95% CI, 0.59-0.82; P < 0.001). CONCLUSION: Low circulating estradiol independently increases the risk of MASLD and high-risk fibrosis in women. While its protective effect against steatosis weakens with obesity, its antifibrotic effect remains strong across all subgroups. Estradiol may serve as an important hormonal marker for risk stratification in female MASLD patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06843421.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
- Department of Biomedical Sciences, Graduate School of Ajou University, Suwon, Korea.
- BK21 R&E Initiative for Advanced Precision Medicine, Ajou University School of Medicine, Suwon, Korea.
- Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea.
- Department of Gastroenterology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
- Department of Cardiology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
ORCID-Profile: Hyo Jung Cho, Seong Hee Kang, Hye Yeon Chon, SungA Bae, Eunju Kim, Seong Kyun Na, Su Jin Kim, Dooyeon Kim, Hye Ri Ahn, Huigyeong Kim, Jae Youn Cheong, Soon Koo Baik, Young Kul Jung, Soon Sun Kim, Hyung Joon Yim
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ajou University Medical Center
Zitieren
APA
Cho, H. J., Kang, S. H., Chon, H. Y., Bae, S., Kim, E., Na, S. K., Kim, S. J., Kim, D., Ahn, H. R., Kim, H., Cheong, J. Y., Baik, S. K., Jung, Y. K., Kim, S. S., & Yim, H. J. (2026). Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort. Journal of Korean Medical Science, 41(42). https://doi.org/10.3346/jkms.2026.41.e258
Vancouver
Cho HJ, Kang SH, Chon HY, Bae S, Kim E, Na SK, et al. Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort. Journal of Korean Medical Science. 2026;41(42). doi:10.3346/jkms.2026.41.e258
BibTeX
@article{Cho2026,
author = {Cho, Hyo Jung and Kang, Seong Hee and Chon, Hye Yeon and Bae, SungA and Kim, Eunju and Na, Seong Kyun and Kim, Su Jin and Kim, Dooyeon and Ahn, Hye Ri and Kim, Huigyeong and Cheong, Jae Youn and Baik, Soon Koo and Jung, Young Kul and Kim, Soon Sun and Yim, Hyung Joon},
title = {Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort},
journal = {Journal of Korean Medical Science},
year = {2026},
volume = {41},
number = {42},
doi = {10.3346/jkms.2026.41.e258}
}
EUVIMED